Cytotherapy · 2026
Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Xuezhu, Lin Zujie, Liu Rui, Yang Yun, Zhao Wanhong, Wang Fangxia, Zhang Wanggang, Liu Jie, Lei Bo, Wang Baiyan, Gu Liufang, He Aili, Bai Ju
Аннотация
BACKGROUND AIMS: Chimeric antigen receptor (CAR) T-cell therapy has significant benefits in the treatment of relapsed/refractory multiple myeloma (R/R MM). Despite the established correlation between nutritional status and the unfavorable prognosis of hematologic malignancies, there remains a paucity of knowledge concerning its predictive value in relation to outcomes and complications arising from CAR T-cell immunotherapy.
METHODS: A retrospective study was conducted based on the LEGEND-2 clinical trial (Xi'an site of phase 1) to evaluate the impact of scores derived from three nutritional and immunologic scoring systems-Controlling Nutritional Status (CONUT), prognostic nutritional index (PNI) and modified Glasgow Prognostic Score (mGPS)-on outcomes and complications after CAR T-cell therapy.
RESULTS: All patients (N = 57) were eligible for the CONUT and PNI, and 24 patients were available for the mGPS. The nutritional status of R/R MM patients who underwent CAR T-cell immunotherapy initially exhibited a decline within the first 2 weeks followed by an improvement 3 weeks after CAR T-cell therapy. We found that an elevated baseline CONUT score (>4) was a risk factor for severe early neutropenia, disseminated intravascular coagulation, prolonged activated partial thromboplastin time and decreased fibrinogen. Low PNI levels (<36.5) were associated with an elevated incidence of hypogammaglobulinemia. Finally, we found an association between baseline mGPS and progression-free survival.
CONCLUSIONS: The CONUT score, PNI and mGPS prior to CAR T-cell immunotherapy offer novel insights into risk stratification in R/R MM patients. Baseline malnutrition might facilitate clinicians in the identification of vulnerable patients to prevent or reduce adverse events and provide individualized management at an early stage.
METHODS: A retrospective study was conducted based on the LEGEND-2 clinical trial (Xi'an site of phase 1) to evaluate the impact of scores derived from three nutritional and immunologic scoring systems-Controlling Nutritional Status (CONUT), prognostic nutritional index (PNI) and modified Glasgow Prognostic Score (mGPS)-on outcomes and complications after CAR T-cell therapy.
RESULTS: All patients (N = 57) were eligible for the CONUT and PNI, and 24 patients were available for the mGPS. The nutritional status of R/R MM patients who underwent CAR T-cell immunotherapy initially exhibited a decline within the first 2 weeks followed by an improvement 3 weeks after CAR T-cell therapy. We found that an elevated baseline CONUT score (>4) was a risk factor for severe early neutropenia, disseminated intravascular coagulation, prolonged activated partial thromboplastin time and decreased fibrinogen. Low PNI levels (<36.5) were associated with an elevated incidence of hypogammaglobulinemia. Finally, we found an association between baseline mGPS and progression-free survival.
CONCLUSIONS: The CONUT score, PNI and mGPS prior to CAR T-cell immunotherapy offer novel insights into risk stratification in R/R MM patients. Baseline malnutrition might facilitate clinicians in the identification of vulnerable patients to prevent or reduce adverse events and provide individualized management at an early stage.